Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13340380 | 0.90 | USP30 (0.42) | NOS2 | |
| SCHEMBL3494485 | 0.81 | CNR2 (0.41) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3492045 | 0.81 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3492063 | 0.77 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3491924 | 0.77 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3494849 | 0.76 | HCRTR1 (0.46) | NPC1RAB9ASMN1; SMN2HCRTR2MAPT | |
| SCHEMBL3493665 | 0.75 | BCL2 (0.38) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3495346 | 0.75 | SMN1; SMN2 (0.41) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3491571 | 0.75 | CNR2 (0.39) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3493404 | 0.75 | ALDH1A1 (0.39) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | RIPK1 4389/4885VCP 3529/4885NTRK1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.